The role of PARP inhibitors for the treatment of oncological diseases has been investigated and it has been reported that PARP‐1 inhibitors may be efficacious in the management of myocardial infarction, cardiopulmonary bypass, and chronic heart failure [416, 417, 418]. Here, PARP1 is linked to congestive heart failure.